The Impact of COVID-19 on EU Cancer Services: Evolution or Revolution?
This event has passed
Members Only - Register herehttps://us06web.zoom.us/meeting/register/tZAvdetrT0tHtVAXRlYd9kpp7B4A9uL2EkH
Overview: COVID-19 created unprecedented challenges for healthcare systems, specifically cancer services. Cancer centres rapidly had to adjust care pathways, reallocate resources, shift cancer services out of the hospital to community settings, communicate with patients remotely rather than face-to-face and often adjust treatment pathways to reflect the new risks facing both healthcare professionals (HCPs) and patients. HCPs had to adapt quickly to new innovations, sometimes challenging their perspectives around what was beneficial to patient care.
A couple of years on, are these innovations still in place? How beneficial do healthcare professionals feel these are to patient care? Has COVID-19 driven an evolution or revolution in both thinking and practice? What challenges are health services still facing? Are biopharma and diagnostic companies aligned to the ‘new normal’?
7i Group conducted a self-funded piece of primary research with European oncologists to answer some of these questions. This webinar will share these findings and explore the potential implications these have for biopharma and diagnostic companies. If COVID-19 has been a catalyst for change, shouldn’t pharma follow and how should they adapt to changes in mindsets and service adaptations?
Biography of presenter:
Claire Jackson, Research Director, 7i Group
Claire has over 18 years of experience in healthcare market research, specifically within UK domestic and European research. She has worked across a wide spectrum of qualitative and quantitative methodologies, covering numerous disease areas, across all types of healthcare stakeholders Disease area coverage includes oncology; prostate cancer, renal cancer carcinoma, MCL, CLL, AML, MM, glioblastoma, breast cancer, lung cancer and colorectal cancers.